ibandronic acid

Also found in: Dictionary, Wikipedia.

ibandronic acid

Pharmacologic class: Bisphosphonate

Therapeutic class: Calcium regulator

Pregnancy risk category C


Inhibits osteoclast activity and reduces bone resorption and turnover; in postmenopausal women, reduces elevated bone turnover rate, leading to (on average) net gain in bone mass


Solution for injection: 3 mg/3 ml in single-use prefilled glass syringes

Tablets (film-coated): 2.5 mg, 150 mg

Indications and dosages

Osteoporosis treatment and prevention in postmenopausal women

Adults: 2.5-mg tablet P.O. daily, or 150-mg tablet P.O. once monthly on same date each month

Osteoporosis treatment in postmenopausal women

Adults: 3 mg I.V. injection every 3 months


• Hypersensitivity to drug or its components
• Uncorrected hypocalcemia
• Inability to stand or sit upright for at least 60 minutes (after oral administration)
• Abnormalities of esophagus, such as stricture or achalasia, that delay esophageal emptying (tablets)


Use cautiously in:
• severe renal impairment (not recommended)
• active upper GI disease (such as Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers)
• patients who develop jaw osteonecrosis during therapy
• concurrent use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or other bisphosphonates
• pregnant or breastfeeding patients
• children younger than age 18 (safety and efficacy not established).


• With patient standing or sitting upright, give oral dose with 6 to 8 oz water at least 60 minutes before first food or drink (other than water) of day or before administering other oral drugs or supplements (including calcium, antacids, and vitamins).
• Give with plain water only; some mineral waters may have higher calcium concentration and shouldn't be used.
• Don't let patient chew or suck tablet because this may cause oropharyngeal ulcers.
• Keep patient upright for at least 60 minutes after oral dose to avoid serious esophageal irritation.
• Give parenteral formulation only by I.V. injection over 15 to 30 seconds.
• Don't mix parenteral formulation with calcium-containing solutions or other I.V. drugs.
• If patient misses I.V. dose, give it as soon as possible; thereafter, give dose every 3 months from date of last injection. Don't administer more often than every 3 months.

Adverse reactions

CNS: insomnia, asthenia, headache, fatigue, dizziness, vertigo, nerve root lesion

CV: hypertension

EENT: pharyngitis

GI: constipation, diarrhea, vomiting, abdominal pain, dysphagia, esophagitis, esophageal irritation (tablets), gastric ulcer, dyspepsia, gastritis, esophageal ulcer

GU: urinary tract infection

Metabolic: hypercholesterolemia, hypocalcemia

Musculoskeletal: osteonecrosis (mainly in jaw), localized osteoarthritis and muscle cramp, joint disorder, joint pain, muscle pain, back pain, extremity pain, arthritis

Respiratory: upper respiratory tract infection, bronchitis, pneumonia

Skin: rash

Other: tooth disorder, influenza, infection, injection site reaction, allergic reaction


Drug-drug.Aspirin, NSAIDs: additive GI irritation

Drugs containing calcium and other multivalent cations (such as aluminum, iron, magnesium), including antacids, supplements, and vitamins: interference with ibandronate absorption

Drug-diagnostic tests.Alkaline phosphatase, calcium: decreased

Bone-imaging agents: interference with test results

Drug-food.Milk, mineral water, other foods and beverages: interference with ibandronate absorption, reducing drug's bioavailability and effect on bone mineral density (when patient consumes food or beverage less than 60 minutes after ibandronate dose)

Patient monitoring

• Monitor creatinine clearance in patients with mild or moderate renal impairment.

Monitor for signs and symptoms of GI irritation (including ulcers) after oral administration; discontinue drug if new or worsening symptoms occur.
• Evaluate serum calcium and phosphate levels.
• Monitor for hypocalcemia and other disturbances of bone and mineral metabolism; administer effective treatment before therapy starts.
• Monitor patient for adequate intake of supplemental calcium and vitamin D during therapy, as appropriate.

Patient teaching

• Advise patient to read patient information leaflet carefully before starting drug.
• Instruct patient to take drug first thing in morning on empty stomach with 6 to 8 oz of plain water only.

Caution patient not to chew or suck tablet because this may cause throat ulcers.
• Instruct patient not to eat, drink, or take other oral medications for 60 minutes after taking tablet.

Caution patient not to lie down for at least 60 minutes after taking drug.
• Advise patient to take once-monthly tablet (150 mg) on same date each month.
• If patient misses once-monthly dose and next scheduled dose is more than 7 days away, instruct her to take one 150-mg tablet in morning after the day she remembers it and then resume taking one 150-mg tablet every month in morning of chosen day, per original schedule. However, if next scheduled dose is only 1 to 7 days away, tell her to wait until next scheduled dose.

Instruct patient to stop drug and immediately report heartburn, serious vomiting, severe chest or abdominal pain, difficulty swallowing, severe bone, joint, or muscle pain.
• If drug is prescribed for injection, tell patient she will receive it every 3 months.
• Advise patient to take supplemental calcium and vitamin D as prescribed, if dietary intake is inadequate.
• Teach patient to take only those pain relievers recommended by prescriber. Point out that some over-the-counter pain preparations (such as aspirin and NSAIDs) may worsen adverse effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

ibandronic acid

A biphosphonate drug that act directly on bone to inhibit osteoclastic activity. The drug is used to treat high levels of blood calcium caused by malignant tumours whether or not bone secondaries are present. It is also used to prevent pathological fractures. A brand name is Bondronate.
References in periodicals archive ?
We are excited to be adding generic Ibandronic Acid to our strong portfolio of more than 350 products in the UK and 340 products in Italy, as we continue to deliver on our commitment of providing high quality and affordable medicines to patients around the world.
The open-label study of 127 patients with breast cancer and bone metastases showed no clinically relevant changes in serum creatinine (SCr) levels in either group, indicating that patients were unlikely to suffer any renal impairment as a consequence of ibandronic acid therapy.
Mylan EMEA President Didier Barret said: "We are excited to be adding generic Ibandronic Acid to our strong portfolio of more than 350 products in the UK and 340 in Italy.
Patients should take once-monthly ibandronic acid with plain water on an empty stomach upon rising in the morning, like other bisphosphonates.
Like other bisphosphonates, ibandronic acid, administered orally, may cause upper gastrointestinal disorders such as pain or difficulty swallowing and stomach ulcers
Supply of low molecular weight heparins, antibiotics, medicines different infusion solutions, human immunoglobulin, the type of water Respiflo products parenteral and enteral nutrition and medicinal products: Ibandronic acid, Rituximab, Etanercept, Adalimumab, Tocilizumab, Infliximab, Rivaroxaban,
Tenders are invited for Supply Of Medicines, Inj Filgrastim 300mcg, Tab Mycophenolate Mofetil 500mg, Tab Ibandronic acid 150mg, Tab Calten-D, Tab.
Supply of low molecular weight heparin, antibiotics, drugs different sera, Antitetanus immunoglobulin, human immunoglobulin, enteral nutrition, parenteral nutrition, infusion, neurological drugs, contrast agents and medicinal products: Ibandronic Acid, Rituximab, Etanercept, Adalimumab, Tocilizumab, Infliximab, Rivaroxaban.
Delivery of low molecular weight heparin, antibiotics, various sera, tetanus immunoglobulin, human immunoglobulin, enteral nutrition, parenteral nutrition, infusion fluids, medicines, neurological, contrast agents and medicinal products: Ibandronic Acid, Rituximab, Etanercept, Adalimumab, Tocilizumab, Infliximab, Rivaroxaban.